Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Treatment of Patients With Major Depressive Disorder With MK0869

This study has been completed.
Sponsor:
Information provided by:
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00034983
First received: May 2, 2002
Last updated: July 31, 2008
Last verified: July 2008

May 2, 2002
July 31, 2008
October 2001
Not Provided
Long-term safety and tolerability. [ Time Frame: Duration of treatment ] [ Designated as safety issue: Yes ]
Not Provided
Complete list of historical versions of study NCT00034983 on ClinicalTrials.gov Archive Site
Sexual dysfunction adverse experiences and gastrointestinal disturbance adverse experiences [ Time Frame: Duration of treatment ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Treatment of Patients With Major Depressive Disorder With MK0869
A Worldwide, Multicenter, Double-Blind, Parallel, Active-Controlled, Long-Term Safety Study of MK0869 in Outpatients With Major Depressive Disorder

A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression

The duration of treatment is 1 year.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Major Depressive Disorder
  • Drug: aprepitant
    Other Name: MK0869
  • Drug: Comparator: paroxetine HCL
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
900
April 2004
Not Provided

Major Depressive Disorder

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00034983
2006_407, Formally-497B, MK0869-066
Not Provided
Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
July 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP